Leave no one behind: inclusion of alpha-1 antitrypsin deficiency patients in COVID-19 vaccine trials

The coronavirus disease of 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, continues to present an unprecedented challenge worldwide. Emerging evidence suggests that α-1 antitrypsin (A1AT), a circulating protein with protective effects on...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chengliang, Zhao, Hedi, Tebbutt, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794731/
https://www.ncbi.nlm.nih.gov/pubmed/35087186
http://dx.doi.org/10.1038/s41431-022-01047-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794731/
https://www.ncbi.nlm.nih.gov/pubmed/35087186
http://dx.doi.org/10.1038/s41431-022-01047-4

Ejemplares similares